Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
A phase 3 trial of Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig in biliary tract cancer, run by AstraZeneca, now recruiting.
Overview
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer is a phase 3 interventional study registered as NCT06467357 by AstraZeneca, with 620 participants planned, started 2024-08-12 and due to reach its primary completion in 2028-06-12. Interventions recorded: Gemcitabine, Cisplatin, Durvalumab, Trastuzumab deruxtecan and Rilvegostomig.
Similar pages
not linked directly; found by shared links- TrialA Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
Shares Rilvegostomig, Durvalumab, Biliary tract cancer (cholangiocarcinoma), AstraZeneca and the tag pipeline.
- TrialDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialCosiporfin Sodium for Injection Photodynamic Therapy
Shares Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Rilvegostomig, Trastuzumab deruxtecan, Cisplatin, AstraZeneca and the tag pipeline.
- TrialAK112 Combined With Chemotherapy Versus Durvalumab Combined With Chemotherapy in Advanced Biliary Tract Cancer
Shares Durvalumab, Gemcitabine, Biliary tract cancer (cholangiocarcinoma), Cisplatin and the tag pipeline.
- TrialStudy of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialStudy of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer
Shares Durvalumab, Gemcitabine, Cisplatin, AstraZeneca and the tag pipeline.
- TrialSafety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
Shares Durvalumab, Gemcitabine, AstraZeneca and the tag pipeline.